MBIO Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals has a net margin of -- compared to Mustang Bio's net margin of --. Mustang Bio's return on equity of -- beat Armata Pharmaceuticals's return on equity of --.

Mustang Bio has a consensus price target of --, signalling upside risk potential of 6844.44%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $7.00 which suggests that it could grow by 430.3%. Given that Mustang Bio has higher upside potential than Armata Pharmaceuticals, analysts believe Mustang Bio is more attractive than Armata Pharmaceuticals.

Mustang Bio has a beta of 2.143, which suggesting that the stock is 114.262% more volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.914, suggesting its less volatile than the S&P 500 by 8.595%.

Mustang Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Mustang Bio quarterly revenues are --, which are smaller than Armata Pharmaceuticals quarterly revenues of --. Mustang Bio's net income of -$1.4M is lower than Armata Pharmaceuticals's net income of $2.6M. Notably, Mustang Bio's price-to-earnings ratio is -- while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio is -- versus 478.46x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -- compared to Mustang Bio's net margin of --. Mustang Bio's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Mustang Bio has a consensus price target of --, signalling upside risk potential of 6844.44%. On the other hand Perspective Therapeutics has an analysts' consensus of $15.18 which suggests that it could grow by 640.42%. Given that Mustang Bio has higher upside potential than Perspective Therapeutics, analysts believe Mustang Bio is more attractive than Perspective Therapeutics.

Mustang Bio has a beta of 2.143, which suggesting that the stock is 114.262% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

Mustang Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Mustang Bio quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Mustang Bio's net income of -$1.4M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Mustang Bio's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio is -- versus 13.27x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Fortress Biotech has a net margin of -- compared to Mustang Bio's net margin of -87.96%. Mustang Bio's return on equity of -- beat Fortress Biotech's return on equity of --.

Mustang Bio has a consensus price target of --, signalling upside risk potential of 6844.44%. On the other hand Fortress Biotech has an analysts' consensus of $15.33 which suggests that it could grow by 852.38%. Given that Mustang Bio has higher upside potential than Fortress Biotech, analysts believe Mustang Bio is more attractive than Fortress Biotech.

Mustang Bio has a beta of 2.143, which suggesting that the stock is 114.262% more volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.825, suggesting its more volatile than the S&P 500 by 82.547%.

Mustang Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio pays -- of its earnings as a dividend. Fortress Biotech pays out -14.46% of its earnings as a dividend.

Mustang Bio quarterly revenues are --, which are smaller than Fortress Biotech quarterly revenues of $14.6M. Mustang Bio's net income of -$1.4M is higher than Fortress Biotech's net income of -$12.9M. Notably, Mustang Bio's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio is -- versus 0.30x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Mustang Bio's net margin of 35.65%. Mustang Bio's return on equity of -- beat Protalix BioTherapeutics's return on equity of 8.75%.

Mustang Bio has a consensus price target of --, signalling upside risk potential of 6844.44%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 459.85%. Given that Mustang Bio has higher upside potential than Protalix BioTherapeutics, analysts believe Mustang Bio is more attractive than Protalix BioTherapeutics.

Mustang Bio has a beta of 2.143, which suggesting that the stock is 114.262% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.351%.

Mustang Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Mustang Bio quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. Mustang Bio's net income of -$1.4M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, Mustang Bio's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 86.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio is -- versus 4.02x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.